Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

This study is looking for children and young adults aged between 1 and 30 years old. You might be able to take part if you have a solid cancer (not a brain or spinal cord tumour) that has come back after treatment, or if the initial treatment didn't get rid of it completely. Doctors will need to have confirmed your cancer diagnosis.

For some parts of the study, especially if you have Ewing sarcoma, your doctors will check if your cancer has specific genetic markers that mean it might respond well to these treatments. Your general health and how well you can move around will also be checked to make sure you're well enough to take part.

The study has specific criteria for different cancer types and stages. It's really important to talk to your doctor about whether this study is right for you, as they will check all the detailed requirements.

If you decide to take part, you'll first be assigned by chance (like flipping a coin) to receive one of the two drug combinations: Onivyde with talazoparib, or Onivyde with temozolomide. During the first part of the study, the medical team will carefully monitor you to find the best and safest dose of these medicines. This will involve regular visits to the hospital for check-ups, blood tests, and scans to see how the treatment is affecting your cancer and your body.

Once the safest doses are found, more patients will join the study. If you have Ewing sarcoma, you'll also be assigned by chance to one of the two drug combinations, given at the best doses. You'll continue to have regular check-ups, blood tests, and scans to see if the treatment is helping your cancer. The length of time you'll be on the study will depend on how you respond to the treatment, but you will have regular follow-up appointments.